<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799275</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2020-01256</org_study_id>
    <secondary_id>NCI-2020-01256</secondary_id>
    <secondary_id>S1918</secondary_id>
    <secondary_id>S1918</secondary_id>
    <secondary_id>U10CA180888</secondary_id>
    <nct_id>NCT04799275</nct_id>
  </id_info>
  <brief_title>Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma</brief_title>
  <official_title>A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II/III trial compares the side effects and activity of oral azacitidine in&#xD;
      combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide,&#xD;
      doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating&#xD;
      patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP&#xD;
      includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the&#xD;
      lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes&#xD;
      prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy&#xD;
      drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as&#xD;
      oral azacitidine, work in different ways to stop the growth of cancer cells, either by&#xD;
      killing the cells, by stopping them from dividing, or by stopping them from spreading.&#xD;
      Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without&#xD;
      disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine if the addition of CC-486 (oral azacitidine) to R-miniCHOP results in excess&#xD;
      toxicity compared to R-miniCHOP alone that would preclude the combination from being studied&#xD;
      further. (Safety run-in) II. To determine if the CC-486 + R-miniCHOP regimen should be tested&#xD;
      further (Phase III) against the control R-miniCHOP alone based on progression-free survival&#xD;
      (PFS). (Phase II component) III. To compare the overall survival (OS) between CC-486 +&#xD;
      R-miniCHOP and R-miniCHOP alone. (Phase III component)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the feasibility of delivering at least 4 cycles of CC-486 with R-miniCHOP in&#xD;
      this population.&#xD;
&#xD;
      II. To assess toxicity for CC-486 + R-miniCHOP and for R-miniCHOP. III. To compare complete&#xD;
      response rates, as defined by Lugano 2014 classification, between CC-486 + R-miniCHOP and&#xD;
      R-miniCHOP alone.&#xD;
&#xD;
      INTEGRATED CORRELATIVE GERIATRIC ASSESSMENTS:&#xD;
&#xD;
      I. To compare functioning as assessed by the S1918 Comprehensive Geriatric Assessment (S1918&#xD;
      CGA) between participants treated with CC-486 + R-miniCHOP versus R-miniCHOP alone.&#xD;
&#xD;
      II. To evaluate if frailty status (fit/unfit versus [vs] frail/superfrail) as assessed by the&#xD;
      FIL tool is associated with OS.&#xD;
&#xD;
      III. To evaluate if frailty as measured by the FIL tool correlates with the summary frailty&#xD;
      index as measured using components of the S1918 CGA.&#xD;
&#xD;
      BANKING OBJECTIVE:&#xD;
&#xD;
      I. To bank specimens for future correlative studies.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Beginning 7 days prior to starting [protocol treatment, all patients receive vincristine&#xD;
      sulfate intravenously (IV) on day 1, and prednisone orally (PO) daily on days 1-7.&#xD;
&#xD;
      Patients are then randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive CC-486 PO for 7 days prior to cycle 1. Patients then receive CC-486&#xD;
      PO on days 8-21. Treatment repeats every 21 days for cycles 1-5 in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients also receive rituximab IV (or subcutaneously&#xD;
      [SC] for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine&#xD;
      sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for&#xD;
      cycles 1-6 (6 cycles total) in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive rituximab IV (or SC for cycles 2-6), cyclophosphamide IV,&#xD;
      doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days&#xD;
      1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically until 5 years from&#xD;
      the date of registration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Excess toxicity as a result of adding oral azacitidine (CC-486) to reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-miniCHOP) (Safety run-in)</measure>
    <time_frame>Up to completion of cycle 6</time_frame>
    <description>Will determine if the addition of CC-486 to R-miniCHOP results in excess toxicity compared to R-miniCHOP alone that would preclude the combination from being studied further.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) (Phase II)</measure>
    <time_frame>From date of registration to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 1 year</time_frame>
    <description>Will determine if the CC-486 + R-miniCHOP regimen should be tested further (Phase III) against the control R-miniCHOP alone based on PFS. After accruing 130 patients (65 per arm, 21 months of accrual and potentially pausing accrual for 6 months follow-up to reach a target 63 events across arms), a one-sided stratified .10 log-rank test will inform a go/no-go decision based on sufficient evidence of efficacy to continue to the Phase III portion of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (Phase III)</measure>
    <time_frame>From date of registration to date of death due to any cause, assessed up to 2 years</time_frame>
    <description>Will compare overall survival in the control arm of R-miniCHOP to the experimental arm of CC-486 (oral azacitidine) + R-miniCHOP. Will be evaluated using a 1-sided .025 level stratified logrank test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic complete response (CR)</measure>
    <time_frame>Up to end of cycle 6 or end of treatment</time_frame>
    <description>Will be defined using 2014 Lugano classification. Fisher's exact test will be used to compare CR rates between the experimental arm of CC-486 + R-miniCHOP and the control arm of R-miniCHOP alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Until disease progression, assessed up to 5 years</time_frame>
    <description>Will be assessed using Common Terminology Criteria for Adverse Events version 5. The maximum Grade for each toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. Treatment-related toxicities between arms will be compared using Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Phase III)</measure>
    <time_frame>From date of registration to date of death due to any cause, assessed up to 5 years</time_frame>
    <description>An additional secondary analysis of overall survival of the Phase III comparison will adjust for patients with identified double-hit phenotype in addition to the pre-specified stratification factors. Will also prospectively collect the number of days between diagnostic biopsy and cycle 1 day 1 of therapy for a pre-planned secondary analysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in function (Integrated Correlative Geriatric Assessments Substudy)</measure>
    <time_frame>From time of randomization up to 24 months after date of registration</time_frame>
    <description>Will be assessed by a Comprehensive Geriatric Assessment (Carolina Frailty Index [CFI] Score) between patients treated with CC-486 + R-miniCHOP and those treated with R-miniCHOP alone. Linear regression will be used for each examination, adjusting for the stratification factors from the clinical study and the baseline score (for the examination of change from 12 to 24 months, the 12-month score will be considered the baseline score). Although the number of timepoints is limited to 3, longitudinal assessments of the CFI Score over time will also be conducted using linear mixed models, adjusting for the stratification factors and the baseline score, with patient considered a random effect.</description>
  </other_outcome>
  <other_outcome>
    <measure>Frailty status (fit/unfit vs frail) (Integrated Correlative Geriatric Assessments Substudy)</measure>
    <time_frame>Baseline</time_frame>
    <description>Will evaluate if frailty status (fit/unfit versus frail) as assessed by the Italian Lymphoma Foundation (FIL) tool is associated with overall survival. Multivariable Cox regression will be conducted, adjusting for the stratification variables and the randomized treatment arm as covariates. Will also examine whether randomization to CC-486 + R-miniCHOP is associated with better overall survival compared to treatment with R-miniCHOP alone in the subset of fit and unfit patients. Multivariable Cox regression will be conducted, adjusting for the stratification variables as covariates.</description>
  </other_outcome>
  <other_outcome>
    <measure>Frailty status (Integrated Correlative Geriatric Assessments Substudy)</measure>
    <time_frame>Up to 24 months after date of registration</time_frame>
    <description>Will evaluate if frailty status (fit/unfit versus frail) as assessed by the FIL tool correlates with the summary frailty indexed as measured by the S1918 Comprehensive Geriatric Assessment (CGA). In particular, agreement between the FIL and CGA will measured using an unweighted Kappa statistic; moderate or better agreement is defined as a Kappa coefficient of &gt;= 0.41.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">422</enrollment>
  <condition>Ann Arbor Stage III Diffuse Large B-Cell Lymphoma</condition>
  <condition>Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma</condition>
  <condition>Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma</condition>
  <condition>Diffuse Large B-Cell Lymphoma Activated B-Cell Type</condition>
  <condition>Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation</condition>
  <condition>Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type</condition>
  <condition>Diffuse Large B-Cell Lymphoma, Not Otherwise Specified</condition>
  <condition>EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified</condition>
  <condition>Grade 3b Follicular Lymphoma</condition>
  <condition>HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified</condition>
  <condition>High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements</condition>
  <condition>High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements</condition>
  <condition>High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements</condition>
  <condition>High Grade B-Cell Lymphoma, Not Otherwise Specified</condition>
  <condition>Intravascular Large B-Cell Lymphoma</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <condition>Nodular Lymphocyte Predominant Hodgkin Lymphoma</condition>
  <condition>Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type</condition>
  <condition>T-Cell/Histiocyte-Rich Large B-Cell Lymphoma</condition>
  <condition>Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma</condition>
  <condition>Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I (oral azacitidine, R-miniCHOP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive CC-486 PO for 7 days prior to cycle 1. Patients then receive CC-486 PO on days 8-21. Treatment repeats every 21 days for cycles 1-5 in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV (or SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for cycles 1-6 (6 cycles total) in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (R-miniCHOP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive rituximab IV (or SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (oral azacitidine, R-miniCHOP)</arm_group_label>
    <arm_group_label>Arm II (R-miniCHOP)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (oral azacitidine, R-miniCHOP)</arm_group_label>
    <arm_group_label>Arm II (R-miniCHOP)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin HCl</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Azacitidine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (oral azacitidine, R-miniCHOP)</arm_group_label>
    <other_name>CC-486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (oral azacitidine, R-miniCHOP)</arm_group_label>
    <arm_group_label>Arm II (R-miniCHOP)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (oral azacitidine, R-miniCHOP)</arm_group_label>
    <arm_group_label>Arm II (R-miniCHOP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Arm I (oral azacitidine, R-miniCHOP)</arm_group_label>
    <arm_group_label>Arm II (R-miniCHOP)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab ABBS</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar JHL1101</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>Rituximab Biosimilar SIBP-02</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>rituximab-abbs</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (oral azacitidine, R-miniCHOP)</arm_group_label>
    <arm_group_label>Arm II (R-miniCHOP)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine Sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have histologically or cytologically confirmed diffuse large B-cell&#xD;
             lymphoma (DLBCL), Ann Arbor stage IIX (bulky), III or IV. Participants with DLBCL&#xD;
             transformed from follicular lymphoma (FL) or marginal zone lymphoma (MZL, including&#xD;
             mucosa-associated lymphoid tissue [MALT] lymphomas), lymphoplasmacytic lymphoma (LPL),&#xD;
             or nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) are eligible. Participants&#xD;
             with grade IIIB follicular lymphoma (FL) and high-grade B-cell lymphomas with MYC and&#xD;
             BCL2 and/or BCL6 rearrangements are also eligible. Participants with DLBCL that arose&#xD;
             from prior chronic lymphocytic leukemia (CLL) (Richter's transformation) are not&#xD;
             eligible&#xD;
&#xD;
          -  As defined by the World Health Organization (WHO), eligible lymphoma subtypes include&#xD;
             the following:&#xD;
&#xD;
               -  DLBCL, not otherwise specified (NOS)&#xD;
&#xD;
               -  DLBCL, germinal-center B-cell type (GCB)&#xD;
&#xD;
               -  DLBCL, activated B-cell type (ABC)&#xD;
&#xD;
               -  T-cell histiocyte-rich B-cell lymphomas (THRBCL)&#xD;
&#xD;
               -  Primary cutaneous DLBCL, leg type&#xD;
&#xD;
               -  Intravascular large B cell lymphoma&#xD;
&#xD;
               -  EBV+ DLBCL, NOS&#xD;
&#xD;
               -  DLBCL associated with chronic inflammation&#xD;
&#xD;
               -  HHV8+ DLBCL, NOS&#xD;
&#xD;
               -  High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements&#xD;
&#xD;
               -  High grade B-cell lymphoma, NOS&#xD;
&#xD;
               -  Follicular lymphoma grade 3b&#xD;
&#xD;
          -  Staging imaging must have occurred within 28 days prior to registration. Positron&#xD;
             emission tomography (PET)-computed tomography (CT) baseline scans are strongly&#xD;
             preferred; diagnostic quality magnetic resonance imaging (MRI), contrast-enhanced CT,&#xD;
             or contrast-enhanced MRI scans are also acceptable if PET-CT is not feasible at&#xD;
             baseline. Note: PET-CT will be required at end of treatment (EOT) and progression for&#xD;
             response assessment. All measurable lesions must be assessed within 28 days prior to&#xD;
             registration. Tests to assess non-measurable disease must be performed within 42 days&#xD;
             prior to registration&#xD;
&#xD;
          -  Participants with known human immunodeficiency virus (HIV)-infection are eligible&#xD;
             providing they are on effective anti-retroviral therapy and have undetectable viral&#xD;
             load at their most recent viral load test (must be within 26 weeks prior to&#xD;
             registration). Participants with known HIV must have a CD4 count checked within 28&#xD;
             days before starting therapy, but may proceed with therapy regardless of CD4 count&#xD;
&#xD;
          -  All participants must be screened for chronic hepatitis B virus (HBV) within 28 days&#xD;
             prior to registration. Participants with known HBV infection (positive serology) must&#xD;
             also have a HBV viral load performed within 28 days prior to registration, and&#xD;
             participants must have an undetectable HBV viral load on suppressive therapy within 28&#xD;
             days prior to registration. Participants found to be HBV carriers during screening are&#xD;
             eligible and must receive standard of care prophylaxis. Participants with active&#xD;
             hepatitis B (HBV viral load &gt; 500 IU/mL) within 28 days prior to registration are not&#xD;
             eligible&#xD;
&#xD;
          -  Participants with a known history of hepatitis C virus (HCV) infection must have an&#xD;
             undetectable HCV viral load within in 28 days prior to registration&#xD;
&#xD;
          -  Participants must have a Zubrod performance status of 0-2&#xD;
&#xD;
          -  Participants must have adequate renal function, as demonstrated by a creatinine&#xD;
             clearance, calculated by the Cockcroft and Gault formula, of &gt;= 30 ml/min that was&#xD;
             obtained within 28 days prior to registration&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) =&lt; 2.5 x institutional upper limit of normal (IULN),&#xD;
             alanine aminotransferase (ALT) =&lt; 2.5 x IULN (within 28 days prior to registration)&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 x institutional upper limit of normal (IULN), unless due to&#xD;
             Gilbert's disease, hemolysis, or lymphomatous involvement of liver (within 28 days&#xD;
             prior to registration). Note: If total bilirubin is elevated, and direct bilirubin is&#xD;
             subsequently performed (within 28 days prior to registration) and resulted to be =&lt; 2&#xD;
             x IULN, the participant will be considered eligible&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1000/mcL (within 28 days prior to registration)&#xD;
&#xD;
          -  Platelets &gt;= 75,000/mcL (within 28 days prior to registration)&#xD;
&#xD;
          -  If there is a documented lymphomatous involvement of the bone marrow, bone marrow&#xD;
             function within 28 days prior to registration, as evidenced by:&#xD;
&#xD;
               -  ANC &gt;= 500/mcL&#xD;
&#xD;
               -  Platelets &gt;= 50,000/mcL&#xD;
&#xD;
          -  Participants must have a left ventricular ejection (LVEF) fraction &gt;= 45% as measured&#xD;
             by echocardiogram or radionuclide (multigated acquisition scan [MUGA])&#xD;
             ventriculography within 56 days prior to registration&#xD;
&#xD;
          -  For the duration of the study treatment period and for at least 4 months following the&#xD;
             last dose of study drug, male participants must agree to use effective contraceptive&#xD;
             methods during sexual contact with a female of childbearing potential (FCBP) and must&#xD;
             agree to refrain from semen or sperm donation during the same timeframe. Effective&#xD;
             contraceptive methods include a history of vasectomy, use of hormonal contraception or&#xD;
             an intrauterine device (IUD) by the female partner, or use of condoms&#xD;
&#xD;
               -  A FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or&#xD;
                  bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least&#xD;
                  24 consecutive months (i.e., has had menses at any time in the preceding 24&#xD;
                  consecutive months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not have known lymphomatous involvement of the central nervous&#xD;
             system (CNS)&#xD;
&#xD;
          -  Participants must not have active inflammatory bowel disease (such as, Crohn's&#xD;
             disease, ulcerative colitis), celiac disease (i.e., sprue), prior gastrectomy or upper&#xD;
             bowel removal, or any other gastrointestinal disorder or defect that would interfere&#xD;
             with the absorption, distribution, metabolism, or excretion of the study drug and/or&#xD;
             predispose the subject to an increased risk of gastrointestinal toxicity&#xD;
&#xD;
          -  Participants must not have received any prior cytotoxic chemotherapy or rituximab for&#xD;
             treatment of the newly diagnosed DLBCL. Participants who received a short course of&#xD;
             glucocorticoids (=&lt; 7 days) per the pre-phase are eligible. Inhaled, nasal, and&#xD;
             topical steroid use is allowed. Prior cytotoxic chemotherapy and/or antibody therapy&#xD;
             for an indolent lymphoma prior to transformation is allowed&#xD;
&#xD;
          -  Participants must not have received more than a cumulative of 250 mg/m^2 of prior&#xD;
             anthracycline therapy (at any time prior to registration)&#xD;
&#xD;
          -  Participants must not currently be receiving any other investigational agents&#xD;
&#xD;
          -  Participant must not have a history of allergic reactions attributed to azacitidine,&#xD;
             mannitol, or other hypomethylating agents&#xD;
&#xD;
          -  Participants must not have active infection (systemic fungal, bacterial, or viral&#xD;
             infection) that is not controlled (defined as ongoing signs/symptoms related the&#xD;
             infection without improvement despite appropriate antibiotics, antiviral therapy,&#xD;
             and/or other treatment)&#xD;
&#xD;
          -  Participants must not have active cardiac disease within 26 weeks prior to&#xD;
             registration, including: symptomatic congestive heart failure (New York Heart&#xD;
             Association [NYHA] class 4), unstable angina pectoris, hemodynamically unstable&#xD;
             cardiac arrhythmia, or myocardial infarction&#xD;
&#xD;
          -  Participants must not have &gt;= grade 2 neuropathy, by Common Terminology Criteria for&#xD;
             Adverse Events (CTCAE) version (v.) 5.0, within 28 days prior to registration&#xD;
&#xD;
          -  Participants must not have any other known uncontrolled intercurrent illness&#xD;
             including, but not limited to ongoing psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth A Brem</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente-Anaheim</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Baldwin Park</name>
      <address>
        <city>Baldwin Park</city>
        <state>California</state>
        <zip>91706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Bellflower</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health Cancer Center-Newport</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-827-8839</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth A. Brem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Fontana</name>
      <address>
        <city>Fontana</city>
        <state>California</state>
        <zip>92335</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Harbor City</name>
      <address>
        <city>Harbor City</city>
        <state>California</state>
        <zip>90710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente West Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Ontario</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth A. Brem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Panorama City</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Riverside</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-San Diego Zion</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-San Marcos</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Woodland Hills</name>
      <address>
        <city>Woodland Hills</city>
        <state>California</state>
        <zip>91367</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-398-3996</phone>
      <email>clinical.trials@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ashraf R. Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delaware Clinical and Laboratory Physicians PA</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>302-623-4450</phone>
      <email>mhayden@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Gregory A. Masters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen F Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>302-623-4450</phone>
      <email>mhayden@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Gregory A. Masters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Hematology Consultants PA</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>302-623-4450</phone>
      <email>mhayden@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Gregory A. Masters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>706-721-2388</phone>
      <email>ga_cares@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Locke J. Bryan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hawaii Cancer Care - Savio</name>
      <address>
        <city>'Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>808-539-2273</phone>
      <email>info@hawaiicancercare.com</email>
    </contact>
    <investigator>
      <last_name>Craig S. Boddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pali Momi Medical Center</name>
      <address>
        <city>'Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>808-486-6000</phone>
    </contact>
    <investigator>
      <last_name>Craig S. Boddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hawaii Cancer Care Inc - Waterfront Plaza</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>808-524-6115</phone>
      <email>i.webster@hawaiicancercare.com</email>
    </contact>
    <investigator>
      <last_name>Craig S. Boddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Cancer Cenrer - POB I</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>808-532-0315</phone>
    </contact>
    <investigator>
      <last_name>Craig S. Boddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>808-545-8548</phone>
    </contact>
    <investigator>
      <last_name>Craig S. Boddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Straub Clinic and Hospital</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>808-522-4333</phone>
    </contact>
    <investigator>
      <last_name>Craig S. Boddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Cancer Center - Kuakini</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>808-531-8521</phone>
    </contact>
    <investigator>
      <last_name>Craig S. Boddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>773-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Sonali M. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Comprehensive Cancer Center at Silver Cross</name>
      <address>
        <city>New Lenox</city>
        <state>Illinois</state>
        <zip>60451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>773-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Sonali M. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine-Orland Park</name>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>773-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Sonali M. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Tanmay Sahai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC - Ames</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>515-239-4734</phone>
      <email>ksoder@mcfarlandclinic.com</email>
    </contact>
    <investigator>
      <last_name>Debra M. Prow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Medical Oncology and Hematology Associates-Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>515-282-2921</phone>
    </contact>
    <investigator>
      <last_name>Joshua Lukenbill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LSU Health Sciences Center at Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>318-813-1404</phone>
      <email>LPost@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Poornima Ramadas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHA Hematology Oncology Consultants-Brighton</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Brighton</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHA Hematology Oncology Consultants-Canton</name>
      <address>
        <city>Canton</city>
        <state>Michigan</state>
        <zip>48188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Canton</name>
      <address>
        <city>Canton</city>
        <state>Michigan</state>
        <zip>48188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHA Hematology Oncology Consultants-Chelsea</name>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <zip>48118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Chelsea</name>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <zip>48118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hope Cancer Clinic</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary Mercy Hospital</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huron Gastroenterology PC</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHA Hematology Oncology Consultants-Ann Arbor</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at West County Hospital</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy L. Bartlett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy L. Bartlett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center-South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy L. Bartlett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Christian Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy L. Bartlett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Saint Peters Hospital</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy L. Bartlett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Partners of Nebraska - Pine Lake</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>402-327-7363</phone>
      <email>research@cancerpartners.com</email>
    </contact>
    <investigator>
      <last_name>Joni A. Tilford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeast Nebraska Cancer Center - 68th Street Place</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>402-327-7363</phone>
      <email>research@cancerpartners.com</email>
    </contact>
    <investigator>
      <last_name>Joni A. Tilford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Colette N. Owens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Englewood Hospital and Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>201-894-3456</phone>
    </contact>
    <investigator>
      <last_name>Adam S. Zayac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monmouth Medical Center Southern Campus</name>
      <address>
        <city>Lakewood</city>
        <state>New Jersey</state>
        <zip>08701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>732-923-6564</phone>
      <email>mary.danish@rwjbh.org</email>
    </contact>
    <investigator>
      <last_name>Kevin A. David</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monmouth Medical Center</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>732-923-6564</phone>
      <email>mary.danish@rwjbh.org</email>
    </contact>
    <investigator>
      <last_name>Kevin A. David</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Colette N. Owens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Colette N. Owens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>732-235-7356</phone>
    </contact>
    <investigator>
      <last_name>Kevin A. David</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Medical Center</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>732-557-8294</phone>
      <email>Lennette.Gonzales@rwjbh.org</email>
    </contact>
    <investigator>
      <last_name>Kevin A. David</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-767-9355</phone>
      <email>askroswell@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Pallawi Torka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Colette N. Owens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Colette N. Owens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-305-6361</phone>
      <email>nr2616@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer E. Amengual</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Colette N. Owens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Colette N. Owens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Southwest Oklahoma Research</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-231-4440</phone>
    </contact>
    <investigator>
      <last_name>Sami Ibrahimi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-603-6213</phone>
      <email>melissa_beckman@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Robert D. Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 13, 2021</study_first_submitted>
  <study_first_submitted_qc>March 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.</ipd_description>
    <ipd_url>https://grants.nih.gov/policy/sharing.htm</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

